



## ASX ANNOUNCEMENT

### Lumos Receives Second US\$5.0 million Hologic IP Agreement Payment

#### Key Highlights

- Second US\$5.0 million payment received from Hologic, Inc. (“Hologic”, NASDAQ: HOLX) under the Intellectual Property (IP) Agreement announced on 11 January 2024
- This second payment, which now brings the total payments under the IP Agreement to US\$10.0 million, grants Hologic an exclusive license in the field of fetal fibronectin (fFN) to Lumos proprietary reader and point-of-care technologies that will be incorporated into their next generation fFN diagnostic product that is under development
- Phase 2 of Development Agreement has commenced, which is focused on assay feasibility

***All amounts are in USD, the Company’s reporting currency, unless otherwise stated.***

**MELBOURNE, Australia (4 June 2024)** – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid point-of-care diagnostic technologies, is pleased to announce that it has received the second payment of US\$5.0 million from Hologic, Inc. (“Hologic”, NASDAQ: HOLX) under the Intellectual Property (IP) Agreement announced on 11 January 2024.

This now brings the total payments received under the IP Agreement to US\$10.0 million.

The IP Agreement provides Hologic with an exclusive license in the field of fetal fibronectin (fFN) to Lumos’ proprietary reader and point of care technologies that will be incorporated into the next generation Hologic fFN diagnostic product under development. The collaboration enhances the test for use on the Lumos proprietary reader platform, incorporating improved connectivity options.

As previously announced on 6 May 2024, Lumos successfully completed Phase 1 of the related Development Agreement, valued at US\$0.4 million, which focused on Product Definition and Planning. This phase is part of a three-phase program with a total value of US\$4.7 million. Payment for Phase 1 is expected by 30 June 2024.

Lumos has commenced Phase 2 of the Development Agreement entitled, "Assay Feasibility", designed to demonstrate that the assay can detect the biomarkers associated with the new fFN test. Successful completion of Phase 2 will trigger a US\$0.6 million payment. The balance of the Development Agreement is payable following the successful completion of Phase 3.

Lumos CEO and Managing Director, Doug Ward commented, *"There is a great need for improved women's health initiatives globally. We are pleased to be associated with leading women's health advocates such as Hologic."*

*"Receiving the second US\$5.0 million payment not only further solidifies our relationship with Hologic, but provides greater balance sheet support and flexibility to execute our long-term strategic goals."*

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

#### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

**Media Contacts:**

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

**Investor Contact:**

Jane Lowe

Managing Director, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 117 774

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598

For personal use only